Recent News

• 04.10.2025 - Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
• 04.10.2025 - Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
• 03.27.2025 - Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
• 03.27.2025 - Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
• 03.27.2025 - Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
• 03.27.2025 - Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
• 03.24.2025 - Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
• 03.24.2025 - Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
• 03.18.2025 - Fourth Quarter 2024 Earnings Conference Call and Webcast
• 03.17.2025 - Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Recent Filings

• 04.07.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 4 Statement of changes in beneficial ownership of securities